MacroGenics (MGNX) to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) will be announcing its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.49). The business had revenue of $10.72 million during the quarter, compared to analysts’ expectations of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. During the same quarter in the previous year, the company posted $0.21 EPS. On average, analysts expect MacroGenics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

MacroGenics Stock Up 3.0 %

MGNX stock opened at $15.67 on Friday. The stock has a market cap of $980.32 million, a price-to-earnings ratio of -97.94 and a beta of 2.09. MacroGenics has a fifty-two week low of $4.29 and a fifty-two week high of $21.88. The business has a 50 day moving average price of $16.46 and a 200 day moving average price of $12.33.

Insider Buying and Selling at MacroGenics

In other MacroGenics news, VP Jeffrey Stuart Peters sold 51,395 shares of MacroGenics stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.55, for a total value of $799,192.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 11.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on MGNX. TheStreet downgraded shares of MacroGenics from a “c” rating to a “d” rating in a research report on Thursday, March 7th. JMP Securities reaffirmed a “market outperform” rating on shares of MacroGenics in a report on Thursday, April 4th. Barclays lifted their target price on MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. TD Cowen raised MacroGenics from a “hold” rating to a “buy” rating in a research report on Tuesday, April 9th. Finally, BTIG Research lifted their price target on MacroGenics from $12.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.